Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 2,666

Not classing aging as a disease is not a major problem

A common concern in the community is that the FDA, the EMA, and other bodies, such as WHO, do not classify aging as a disease and that this poses a problem for developing therapies that target aging. However, this is not really as serious an issue as some people would suggest; today, we will have a look at why that is.

Why this will not stop progress

Aging is a variety of distinct processes, damages, and errors; therefore, simply treating aging in clinical terms is not a viable endpoint. For a clinical trial to be conducted, it requires a verifiable indication, and aging is too general for the FDA and EMA to classify it as a disease.

Mid-week Cancer Study and Emergency Drill Fill Station Schedule

Cancer and rodent studies were on the crew’s timeline today to help doctors and scientists improve the health of humans in space and on Earth. The crew also conducted an emergency drill aboard the International Space Station.

Flight Engineer Serena Auñón-Chancellor examined endothelial cells through a microscope for the AngieX Cancer Therapy study. The new cancer research seeks to test a safer, more effective treatment that targets tumor cells and blood vessels. Commander Drew Feustel partnered with astronaut Alexander Gerst and checked on mice being observed for the Rodent Research-7 (RR-7) experiment. RR-7 is exploring how microgravity impacts microbes living inside organisms.

Astronaut Ricky Arnold and Gerst collected and stowed their blood samples for a pair of ongoing human research studies. Arnold went on to work a series of student investigations dubbed NanoRacks Module-9 exploring a variety of topics including botany, biology and physics.

Celebrating Success at Our First Conference

We brought the leading experts in aging research and biotech investment together for an action-packed day of science. See what happened at this exciting event and check out our first event video now.

On July 12th, we hosted our first conference, Ending Age-Related Diseases: Investment Prospects & Advances in Research, at the Frederick P. Rose Auditorium, which is part of the Cooper Union campus in New York City. We are delighted to announce that the conference was a huge success with 160 attendees, a wide variety of speakers from both research and business, and some great discussion panels.

The goal of this conference was to promote multidisciplinary collaboration in order to foster the development of next-generation drugs and therapies that directly target the processes of aging and thus have the potential to prevent and cure age-related diseases.

For those of you who could not join us there, we have recorded the talks and panels from the conference, and we will be making them available on our website in the next few weeks once we have edited them. As a special thank you, the Lifespan Heroes, our monthly patrons, will be offered early access to these videos ahead of a public release.

Scientists have created an AI inside a test tube using strands of DNA, and they hope it will soon start to form its own ‘memories’

An artificial neural network that’s made entirely from DNA and mimics the way the brain works has been created by scientists in the lab.

The test tube artificial intelligence can solve a classic machine learning problem by correctly identifying handwritten numbers.

The work is a significant step in demonstrating the ability to program AI into man-made organic circuits, scientists claim.

A Novel Gene Therapy To Treat One Of The World’s Biggest Growing Chronic Disease: Dementia and Alzhiemer’s

The brain is about 10% neurons and 90% neural network support cells, called neuroglia, or glial cells, which surround and insulate neurons, protect them from damage, and supply them with nutrients and oxygen. Neuroglia are often found to malfunction in neurological disorders such as Alzheimer’s Disease or amyotrophic lateral sclerosis (ALS).

Research studies indicate that telomerase gene therapy may not only reverse Alzheimer’s Disease and other dementias, but it may even protect people from developing such diseases.

This is indeed hopeful news for the nearly 50 million victims of Alzheimer’s or related dementia worldwide as well as for the millions of aging people with Parkinson’s and aging-related mental decline.

Telomerase gene therapy appears to rejuvenate microglial (the immune cells of the brain) cells in Alzheimer’s Disease according to promising research study data.